Abstract
Background Limited data are available on the application of circulating tumor DNA (ctDNA) in metastatic triple-negative breast cancer (mTNBC) patients. Here, we investigated the value of ctDNA for predicting the prognosis and monitoring the treatment response in mTNBC patients.
Methods We prospectively enrolled 70 Chinese patients with mTNBC who had progressed after ≤ 2 lines of chemotherapy and collected blood samples to extract ctDNA for 457-gene targeted panel sequencing.
Results Patients with ctDNA+, defined by 12 prognosis-relevant mutated genes, had a shorter progression-free survival (PFS) than ctDNA− patients (5.16 months vs. 9.05 months, P = 0.001) and ctDNA+ was independently associated with a shorter PFS (HR, 95%CI: 2.67, 1.2–5.96; P = 0.016) by multivariable analyses. Patients with a higher mutant-allele tumor heterogeneity (MATH) score (≥ 6.316) or a higher ctDNA fraction (ctDNA% ≥ 0.05) had a significantly shorter PFS than patients with a lower MATH score (5.67 months vs.11.27 months, P = 0.007) and patients with a lower ctDNA% (5.45 months vs. 12.17 months, P < 0.001), respectively. Positive correlations with treatment response were observed for MATH score (R = 0.24, P = 0.014) and ctDNA% (R = 0.3, P = 0.002), but not the CEA, CA125, or CA153. Moreover, patients who remained ctDNA+ during dynamic monitoring tended to have a shorter PFS than those who did not (3.90 months vs. 6.10 months, P = 0.135).
Conclusions ctDNA profiling provides insight into the mutational landscape of mTNBC and may reliably predict the prognosis and treatment response of mTNBC patients.
Funding This work was supported by the National Natural Science Foundation of China (Grant No. 81902713), Natural Science Foundation of Shandong Province (Grant No. ZR2019LZL018), Breast Disease Research Fund of Shandong Provincial Medical Association (Grant No. YXH2020ZX066), the Start-up Fund of Shandong Cancer Hospital (Grant No. 2020-PYB10), Beijing Science and Technology Innovation Fund (Grant No. KC2021-ZZ-0010-1).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Because this is a prospective observational study, only tumor tissue or blood samples from patients were taken for analysis and did not interfere with patient treatment, a clinical trial number registration is not required.
Funding Statement
This work was supported by the National Natural Science Foundation of China (Grant No. 81902713), Natural Science Foundation of Shandong Province (Grant No. ZR2019LZL018), Breast Disease Research Fund of Shandong Provincial Medical Association (Grant No. YXH2020ZX066), the Start-up Fund of Shandong Cancer Hospital (Grant No. 2020-PYB10), Beijing Science and Technology Innovation Fund (Grant No. KC2021-ZZ-0010-1). And no external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of Shandong Cancer Hospital and Institute (approval number: SDTHEC201806003) that collection of information, tumor tissues and blood samples within the ethical limitition of the patients, and conducted according to the Declaration of Helsinki. Written informed consent was obtained from all patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The raw sequence data generated during the current study have been deposited in the China National Genomics Data Center (https://ngdc.cncb.ac.cn/gsa-human/). The data under accession HRA002598 will be available on 27 June 2024 and are also available from the corresponding author upon reasonable request.
